Abbott Laboratories (NYSE:ABT) is one of the high profit margin stocks to buy now. On June 19, Beta Bionics Inc. (NASDAQ:BBNX ...

Pain avoidance as a key motivator: Numerous surveys in 2025 indicate that a major reason people avoid consistent health ...

For patients with T2D, disparities in CGM prescriptions are seen by language preference, with less access for adult patients with non-English language preferences.

Point-of-care testing market was valued at US$ 46.48 billion in 2024 and is projected to hit the market valuation of US$ 85.55 billion by 2033 at a CAGR of 7.33% during the forecast period 2025–2033.

The diabetes conference featured a debate about over-the-counter glucose monitors and updates on upcoming devices, including ...

Experts speaking at the ADA’s Scientific Sessions supported making CGMs more accessible, but debated their usefulness for ...

Stocks of companies that sell these devices have seen a surge following his commentary. Abbott Laboratories (ABT) and DexCom ...